Send to

Choose Destination
See comment in PubMed Commons below
J Drugs Dermatol. 2006 Feb;5(2):117-22.

A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.

Author information

Dept of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, NY, 10025, USA.

Erratum in

  • J Drugs Dermatol. 2006 Mar;5(3):table of contents. Schienfeld, Noah [corrected to Scheinfeld, Noah].


Imatinib mesylate (Gleevec, also known as STI-571), is an approved oral treatment for patients with chronic myeloid leukemia (CML). It blocks the activity of Abelson cytoplasmic tyrosine kinase (ABL), c-Kit and the platelet-derived growth factor receptor (PDGFR). As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans. One report notes its effectiveness for treating HIV related Kaposi's sarcoma; imatinib has not been effective for the treatment of melanoma.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center